Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 20 November 2023, 16:05 HKT/SGT
Share:
    

Source: Eisai
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023

TOKYO and CAMBRIDGE, Mass., Nov 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline.

The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.

The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates LEQEMBI as the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline, which acts on the underlying pathology of AD.

The award for Clinical Advance of the Year recognizes the success of a new drug product in a clinical trial that is expected to lead to an advance in healthcare. It was awarded for the success of the Phase III Clarity AD study of LEQEMBI.

Eisai and Biogen deeply appreciate the cooperation of people living with AD and healthcare professionals who participated in LEQEMBI’s clinical studies.

AD is a progressive, fatal disease, and a global healthcare issue that greatly impacts not only the people living with the disease, but also their loved ones, care partners and society. Eisai and Biogen will deliver LEQEMBI to the people with early AD who need it, as well as aim to continue creating impact on global issues surrounding dementia.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product. Eisai has the final decision-making authority.

Please see full Prescribing Information, including Boxed WARNING in the United States.

For more information, visit www.eisai.com/news/2023/news202370.html

Media Contacts:

Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Biogen Inc.
Jack Cox + 1-781-464-3260
public.affairs@biogen.com




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 30, 2023 15:25 HKT/SGT
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Nov 22, 2023 08:28 HKT/SGT
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
Oct 25, 2023 19:43 HKT/SGT
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
Oct 16, 2023 13:07 HKT/SGT
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
Oct 11, 2023 12:07 HKT/SGT
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
Oct 4, 2023 18:08 HKT/SGT
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
Sept 28, 2023 16:05 HKT/SGT
Eisai Launches New "Innovation" Page on Corporate Website
Sept 28, 2023 13:49 HKT/SGT
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
Sept 25, 2023 14:17 HKT/SGT
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Sept 21, 2023 11:26 HKT/SGT
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
More news >>
 News Alerts
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: